Safety Alerts & Recalls
What does this mean?
Since Cubicin is used in the treatment of serious infections, the benefits of this antibiotic will continue to outweigh the risks for most patients. However, if you are receiving Cubicin, you should be aware that eosinophilic pneumonia has been reported in patients receiving Cubicin. If you have any concerns about this new safety information for Cubicin, please follow up with your doctor or other healthcare professional.
If you experience a new or worsening fever, cough, shortness of breath, or have difficulty breathing while receiving Cubicin, contact your doctor or other healthcare professional immediately.
FDA Warns about Risk of Developing Rare Type of Pneumonia During Treatment With Cubicin
Today, the U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia during treatment with Cubicin (daptomycin). Cubicin is an intravenous antibiotic indicated for use in treatment of serious skin infections and bloodstream infections. Eosinophilic pneumonia is a rare but serious condition where a type of white blood cell (eosinophil) fills the lungs. Symptoms of eosinophilic pneumonia include fever, cough, shortness of breath, and difficulty breathing. Eosinophilic pneumonia may lead to serious lung complications and can be fatal if not quickly recognized and managed by doctors.
For more information, please visit: more information here